Topical ruxolitinib does not carry the same safety profile as oral JAK inhibitors for AD, which may warrant reconsideration of the boxed warning.

Experts discuss the unique challenges of managing atopic dermatitis (AD) in pediatric and adolescent patients, emphasizing the strategic use of topical treatments to improve adherence, reduce ...

World Atopic Eczema Day 2025 highlights the lifelong impact of atopic eczema, a common inflammatory skin disease that often begins in infancy and can lead to food allergies, asthma, and other allergic ...

The TL1A inhibitor market is rapidly advancing, driven by significant investments from major biopharmaceutical companies and ...

Recent FDA approvals include new therapies for AD, HS, and plaque psoriasis, impacting patients with skin of color. Tapinarof cream, roflumilast foam, and delgocitinib are notable topical treatments ...

The global dermatology market is driven by increasing skin disorder prevalence, aging demographics, and technological innovations like teledermatology and nanotechnology. The influence of social media ...

The TL1A inhibitor market is rapidly advancing, driven by significant investments from major biopharmaceutical companies and growing confidence in its potential to transform autoimmune disease ...

Eczema, also known as atopic dermatitis, is a chronic, noncontagious skin disorder that causes itchy, scaly patches of skin.

Almirall, S.A. (ALM) a global biopharmaceutical company dedicated to medical dermatology, is a major contributor to the 2025 European Academy of Dermatology and Venereology Congress (EADV) presenting ...

Daewoong Pharmaceutical’s subsidiary ‘Daewoong Pet’ is jointly developing the world’s first treatment for sarcopenia in ...

HKeyBio, a CRO specializing in preclinical and translational autoimmune-drug development, today announced the launch of HKEY-NHP-MATRIX2.0, a next-generation platform designed to improve the ...